Skip to main content

The Rho kinase inhibitor, fasudil, ameliorates diabetes-induced cardiac dysfunction by improving calcium clearance and actin remodeling

Journal of Molecular Medicine volume 95, pages 155–165 (2017)Cite this article

An Erratum to this article was published on 22 September 2016

Abstract

Previous study showed inhibition of RhoA and Rho kinase (ROCK) activity with fasudil could alleviate diabetes-induced cardiac dysfunction partially due to improvement of myocardial fibrosis. However, the effect of fasudil on intracellular calcium cycling and actin remodeling, both of which are important to regulate excitation-contract coupling, is still not fully elucidated. In this study, a diabetic cardiomyopathy model was induced by a single intraperitoneal injection of streptozotocin (STZ) in male Sprague Dawley rats. Diabetic rats were treated with fasudil or placebo for 8 weeks. We found that long-term administration of fasudil, a specific Rho kinase inhibitor, significantly ameliorated diabetes-induced contractile dysfunction both at cellular and whole organ levels. Fasudil-treated rats displayed improved diastolic intracellular calcium ([Ca2+]i) removal and rescued expression of protein responsible for [Ca2+]i clearance. Furthermore, our study indicated that fasudil treatment normalized the phosphorylation of the PKCβ2/Akt pathway in the diabetic heart, which might be the underlying mechanism accounting for the protective effect of fasudil on [Ca2+]i clearance. In addition, compared to the diabetes group, fasudil also normalized the G/F-actin ratio by preventing cofilin phosphorylation and promoted F-actin organization, suggesting a beneficial effect on actin remodeling. These findings indicate the protective effect of fasudil against diabetes-induced cardiac dysfunction via modulation of Ca2+ handling and actin remodeling. Overactivation of RhoA/ROCK plays a key role in the development of DCM. Inhibition of ROCK activity with fasudil improved [Ca2+]i removal in diabetic cardiomyocytes. Fasudil normalized the G/F-actin ratio and promoted F-actin organization. ROCK may be an excellent therapeutic target for the treatment of DCM.

Key message

  • Overactivation of RhoA/ROCK plays a key role in the development of DCM.

  • Inhibition of ROCK activity with fasudil improved [Ca2+]i removal in diabetic cardiomyocytes.

  • Fasudil normalized the G/F-actin ratio and promoted F-actin organization.

  • ROCK may be an excellent therapeutic target for the treatment of DCM.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

References

  1. Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE (2014) Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract 103:137–149

    CAS  Article  PubMed  Google Scholar 

  2. Bayeva M, Sawicki KT, Ardehali H (2013) Taking diabetes to heart—deregulation of myocardial lipid metabolism in diabetic cardiomyopathy. J Am Heart Assoc 2:e000433

    Article  PubMed  PubMed Central  Google Scholar 

  3. Etienne-Manneville S, Hall A (2002) Rho GTPases in cell biology. Nature 420:629–635

    CAS  Article  PubMed  Google Scholar 

  4. Hamid SA, Bower HS, Baxter GF (2007) Rho kinase activation plays a major role as a mediator of irreversible injury in reperfused myocardium. Am J Physiol Heart Circ Physiol 292:H2598–H2606

    CAS  Article  PubMed  Google Scholar 

  5. Li Y, Zhu W, Tao J, Xin P, Liu M, Li J, Wei M (2012) Fasudil protects the heart against ischemia-reperfusion injury by attenuating endoplasmic reticulum stress and modulating SERCA activity: the differential role for PI3K/Akt and JAK2/STAT3 signaling pathways. PLoS One 7:e48115

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  6. Molina-Sanchez P, Chevre R, Rius C, Fuster JJ, Andres V (2015) Loss of p 27 phosphorylation at Ser10 accelerates early atherogenesis by promoting leukocyte recruitment via RhoA/ROCK. J Mol Cell Cardiol 84:84–94

    CAS  Article  PubMed  Google Scholar 

  7. Phrommintikul A, Tran L, Kompa A, Wang B, Adrahtas A, Cantwell D, Kelly DJ, Krum H (2008) Effects of a Rho kinase inhibitor on pressure overload induced cardiac hypertrophy and associated diastolic dysfunction. Am J Physiol Heart Circ Physiol 294:H1804–H1814

    CAS  Article  PubMed  Google Scholar 

  8. Guan SJ, Ma ZH, YL W, Zhang JP, Liang F, Weiss JW, Guo QY, Wang JY, Ji ES, Chu L (2012) Long-term administration of fasudil improves cardiomyopathy in streptozotocin-induced diabetic rats. Food Chem Toxicol 50:1874–1882

    CAS  Article  PubMed  Google Scholar 

  9. Guo R, Su Y, Yan J, Sun H, Wu J, Liu W, Xu Y (2015) Fasudil improves short-term echocardiographic parameters of diastolic function in patients with type 2 diabetes with preserved left ventricular ejection fraction: a pilot study. Heart Vessel 30:89–97

    CAS  Article  Google Scholar 

  10. Lin G, Craig GP, Zhang L, Yuen VG, Allard M, McNeill JH, MacLeod KM (2007) Acute inhibition of Rho-kinase improves cardiac contractile function in streptozotocin-diabetic rats. Cardiovasc Res 75:51–58

    CAS  Article  PubMed  Google Scholar 

  11. Choi KM, Zhong Y, Hoit BD, Grupp IL, Hahn H, Dilly KW, Guatimosim S, Lederer WJ, Matlib MA (2002) Defective intracellular Ca(2+) signaling contributes to cardiomyopathy in type 1 diabetic rats. Am J Physiol Heart Circ Physiol 283:H1398–H1408

    CAS  Article  PubMed  Google Scholar 

  12. Zhao SM, Wang YL, Guo CY, Chen JL, YQ W (2014) Progressive decay of Ca2+ homeostasis in the development of diabetic cardiomyopathy. Cardiovasc Diabetol 13:75

    Article  PubMed  PubMed Central  Google Scholar 

  13. Zhang L, Cannell MB, Phillips AR, Cooper GJ, Ward ML (2008) Altered calcium homeostasis does not explain the contractile deficit of diabetic cardiomyopathy. Diabetes 57:2158–2166

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  14. Zhang L, Ward ML, Phillips AR, Zhang S, Kennedy J, Barry B, Cannell MB, Cooper GJ (2013) Protection of the heart by treatment with a divalent-copper-selective chelator reveals a novel mechanism underlying cardiomyopathy in diabetic rats. Cardiovasc Diabetol 12:123

    Article  PubMed  PubMed Central  Google Scholar 

  15. Yang Y, Lu X, Rong X, Jiang W, Lai D, Ma Y, Zhou K, Fu G, Xu S (2015) Inhibition of the mevalonate pathway ameliorates anoxia-induced down-regulation of FKBP12.6 and intracellular calcium handling dysfunction in H9c2 cells. J Mol Cell Cardiol 80:166–174

    CAS  Article  PubMed  Google Scholar 

  16. Ding D, Du Y, Qiu Z, Yan S, Chen F, Wang M, Yang S, Zhou Y, Hu X, Deng Y, et al. (2016) Vaccination against type 1 angiotensin receptor prevents streptozotocin-induced diabetic nephropathy. J Mol Med 94:207–218

    CAS  Article  PubMed  Google Scholar 

  17. Lai D, Xu L, Cheng J, Guilbert AB, Lim HJ, Fu G, Wang Y (2013) Stretch current-induced abnormal impulses in CaMKIIdelta knockout mouse ventricular myocytes. J Cardiovasc Electrophysiol 24:457–463

    Article  PubMed  Google Scholar 

  18. Cheng J, Xu L, Lai D, Guilbert A, Lim HJ, Keskanokwong T, Wang Y (2012) CaMKII inhibition in heart failure, beneficial, harmful, or both. Am J Physiol Heart Circ Physiol 302:H1454–H1465

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  19. Li L, Chu G, Kranias EG, Bers DM (1998) Cardiac myocyte calcium transport in phospholamban knockout mouse: relaxation and endogenous CaMKII effects. Am J Phys 274:H1335–H1347

    CAS  Google Scholar 

  20. Lei S, Li H, Xu J, Liu Y, Gao X, Wang J, Ng KF, Lau WB, Ma XL, Rodrigues B, et al. (2013) Hyperglycemia-induced protein kinase C beta2 activation induces diastolic cardiac dysfunction in diabetic rats by impairing caveolin-3 expression and Akt/eNOS signaling. Diabetes 62:2318–2328

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  21. Lin G, Brownsey RW, Macleod KM (2014) Complex regulation of PKCbeta2 and PDK-1/AKT by ROCK2 in diabetic heart. PLoS One 9: e86520

  22. Small EM, Thatcher JE, Sutherland LB, Kinoshita H, Gerard RD, Richardson JA, Dimaio JM, Sadek H, Kuwahara K, Olson EN (2010) Myocardin-related transcription factor-a controls myofibroblast activation and fibrosis in response to myocardial infarction. Circ Res 107:294–304

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  23. Soliman H, Craig GP, Nagareddy P, Yuen VG, Lin G, Kumar U, McNeill JH, Macleod KM (2008) Role of inducible nitric oxide synthase in induction of RhoA expression in hearts from diabetic rats. Cardiovasc Res 79:322–330

    CAS  Article  PubMed  Google Scholar 

  24. Waddingham MT, Edgley AJ, Astolfo A, Inagaki T, Fujii Y, CK D, Zhan DY, Tsuchimochi H, Yagi N, Kelly DJ, et al. (2015) Chronic Rho-kinase inhibition improves left ventricular contractile dysfunction in early type-1 diabetes by increasing myosin cross-bridge extension. Cardiovasc Diabetol 14:92

    Article  PubMed  PubMed Central  Google Scholar 

  25. Soliman H, Gador A, YH L, Lin G, Bankar G, MacLeod KM (2012) Diabetes-induced increased oxidative stress in cardiomyocytes is sustained by a positive feedback loop involving Rho kinase and PKC 2. Am J Physiol Heart Circ Physiol 303:H989–H1000

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  26. Guo R, Liu B, Zhou S, Zhang B, Xu Y (2013) The protective effect of fasudil on the structure and function of cardiac mitochondria from rats with type 2 diabetes induced by streptozotocin with a high-fat diet is mediated by the attenuation of oxidative stress. Biomed Res Int 2013:430791

    PubMed  PubMed Central  Google Scholar 

  27. Arita R, Hata Y, Nakao S, Kita T, Miura M, Kawahara S, Zandi S, Almulki L, Tayyari F, Shimokawa H, et al. (2009) Rho kinase inhibition by fasudil ameliorates diabetes-induced microvascular damage. Diabetes 58:215–226

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  28. Pearson JT, Jenkins MJ, Edgley AJ, Sonobe T, Joshi M, Waddingham MT, Fujii Y, Schwenke DO, Tsuchimochi H, Yoshimoto M, et al. (2013) Acute Rho-kinase inhibition improves coronary dysfunction in vivo, in the early diabetic microcirculation. Cardiovasc Diabetol 12:111

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  29. Tada M, Ohmori F, Yamada M, Abe H (1979) Mechanism of the stimulation of Ca2+-dependent ATPase of cardiac sarcoplasmic reticulum by adenosine 3':5'-monophosphate-dependent protein kinase. Role of the 22,000-dalton protein. J Biol Chem 254:319–326

    CAS  PubMed  Google Scholar 

  30. Tada M, Yamada M, Ohmori F, Kuzuya T, Inui M, Abe H (1980) Transient state kinetic studies of Ca2-dependent ATPase and calcium transport by cardiac sarcoplasmic reticulum. Effect of cyclic AMP-dependent protein kinase-catalyzed phosphorylation of phospholamban. J Biol Chem 255:1985–1992

    CAS  PubMed  Google Scholar 

  31. MacLennan DH, Kranias EG (2003) Phospholamban: a crucial regulator of cardiac contractility. Nat Rev Mol Cell Biol 4:566–577

    CAS  Article  PubMed  Google Scholar 

  32. Erickson JR, Pereira L, Wang L, Han G, Ferguson A, Dao K, Copeland RJ, Despa F, Hart GW, Ripplinger CM, et al. (2013) Diabetic hyperglycaemia activates CaMKII and arrhythmias by O-linked glycosylation. Nature 502:372–376

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  33. Pereira L, Ruiz-Hurtado G, Rueda A, Mercadier JJ, Benitah JP, Gomez AM (2014) Calcium signaling in diabetic cardiomyocytes. Cell Calcium 56:372–380

    CAS  Article  PubMed  Google Scholar 

  34. Catalucci D, Latronico MV, Ceci M, Rusconi F, Young HS, Gallo P, Santonastasi M, Bellacosa A, Brown JH, Condorelli G (2009) Akt increases sarcoplasmic reticulum Ca2+ cycling by direct phosphorylation of phospholamban at Thr17. J Biol Chem 284:28180–28187

  35. Gao MH, Tang T, Guo T, Miyanohara A, Yajima T, Pestonjamasp K, Feramisco JR, Hammond HK (2008) Adenylyl cyclase type VI increases Akt activity and phospholamban phosphorylation in cardiac myocytes. J Biol Chem 283:33527–33535

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  36. Yuan B, Wan P, Chu D, Nie J, Cao Y, Luo W, Lu S, Chen J, Yang Z (2014) A cardiomyocyte-specific Wdr1 knockout demonstrates essential functional roles for actin disassembly during myocardial growth and maintenance in mice. Am J Pathol 184:1967–1980

    CAS  Article  PubMed  Google Scholar 

  37. Davani EY, Dorscheid DR, Lee CH, van Breemen C, Walley KR (2004) Novel regulatory mechanism of cardiomyocyte contractility involving ICAM-1 and the cytoskeleton. Am J Physiol Heart Circ Physiol 287:H1013–H1022

    CAS  Article  PubMed  Google Scholar 

  38. Tate M, Robinson E, Green BD, McDermott BJ, Grieve DJ (2016) Exendin-4 attenuates adverse cardiac remodelling in streptozocin-induced diabetes via specific actions on infiltrating macrophages. Basic Res Cardiol 111:1

    CAS  Article  PubMed  Google Scholar 

  39. Li CJ, Lv L, Li H, DM Y (2012) Cardiac fibrosis and dysfunction in experimental diabetic cardiomyopathy are ameliorated by alpha-lipoic acid. Cardiovasc Diabetol 11:73

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  40. Talior-Volodarsky I, Connelly KA, Arora PD, Gullberg D, McCulloch CA (2012) Alpha11 integrin stimulates myofibroblast differentiation in diabetic cardiomyopathy. Cardiovasc Res 96:265–275

    CAS  Article  PubMed  Google Scholar 

  41. Lagna G, MM K, Nguyen PH, Neuman NA, Davis BN, Hata A (2007) Control of phenotypic plasticity of smooth muscle cells by bone morphogenetic protein signaling through the myocardin-related transcription factors. J Biol Chem 282:37244–37255

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  42. Witt W, Buttner P, Jannasch A, Matschke K, Waldow T (2014) Reversal of myofibroblastic activation by polyunsaturated fatty acids in valvular interstitial cells from aortic valves. Role of RhoA/G-actin/MRTF signalling. J Mol Cell Cardiol 74:127–138

    CAS  Article  PubMed  Google Scholar 

Download references

Acknowledgments

We sincerely thank Lu Zhang at Zhejiang University for her excellent technical assistance for confocal microscopy.

Author information

Affiliations

  1. Department of Cardiology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, 3 East Qingchun Road, Hangzhou, Zhejiang Province, 310016, China

    Dongwu Lai, Jing Gao, Xukun Bi, Hong He, Shaoxiang Weng, Ying Yang, Yang Ye & Guosheng Fu

  2. Experimental Research Center, China Academy of Chinese Medical Sciences, Beijing, China

    Xiaolu Shi

  3. Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou, China

    Yu Chen

Authors
  1. Dongwu Lai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jing Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xukun Bi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hong He
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xiaolu Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shaoxiang Weng
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yu Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ying Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yang Ye
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Guosheng Fu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Guosheng Fu.

Ethics declarations

Grant support

This work was supported by grants from the National Natural Science Foundation of China (No. 81100159 and 81100167), Medical and Health Science Program of Zhejiang Province (No. 201477370 and 201646246), Natural Science Foundation of Zhejiang Province (No. LY15H020003), and Health Science and Technology Plan of Hangzhou City (No. 2013A28).

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Dongwu Lai and Jing Gao contributed equally to this work.

An erratum to this article is available at http://dx.doi.org/10.1007/s00109-016-1476-2.

Electronic supplementary material

ESM 1

(PDF 496 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Lai, D., Gao, J., Bi, X. et al. The Rho kinase inhibitor, fasudil, ameliorates diabetes-induced cardiac dysfunction by improving calcium clearance and actin remodeling. J Mol Med 95, 155–165 (2017). https://doi.org/10.1007/s00109-016-1469-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00109-016-1469-1

Keywords

  • Rho kinase
  • Diabetic cardiomyopathy
  • Fasudil
  • Calcium transient
  • Acting remodeling